EDIT Stock — Editas Medicine Inc.: Cash, EV, Pipeline

What they do

We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing.

Source: 10-K FY2025 via SEC EDGAR

Share price

$2.57

Market cap

$394.7M

Cash

$211.6M

Enterprise value

$231.3M

Balance sheet

Cash	$211.6M
Debt	$48.2M
Net cash	$163.4M
Enterprise value	$231.3M
Basic shares	153.6M shares
Fully diluted shares	224.5M shares
Fully diluted market cap	$577.1M
Cash per share	$1.38
Quarterly burn	$29.6M
Cash runway	7.2 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

153.6M

Pre-funded warrants

0.0M

Options

12.3M

RSUs

0.4M

Warrants

55.6M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.7M

FDSO

224.5M

Cap table as of 2026-06-30.

Price history

Loading EDIT daily closes…

Loading price history…

Next catalyst

EDIT-401 · Est. Feb 14, 2027 · quarter midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 8 wks quarter midpoint	EDIT-401 Phase 1/2 trial in heterozygous familial hypercholesterolemia	Phase 1/2	heterozygous familial hypercholesterolemia	Q1 2027 (data update); 2027 (Part 1 topline)

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EDIT-401

Preclinical · Active Modality: In vivo gene editing (LNP-delivered)

Target HBG1/2 promoter (gamma-globin)

Indications

Sickle cell disease / transfusion-dependent beta thalassemia (hemoglobinopathies) (Preclinical)

Status note Lead program: in vivo gene editing for hemoglobinopathies; company focusing resources on advancing to human proof-of-concept.

renizgamglogene autogedtemcel (reni-cel)

Stage not disclosed · Terminated Modality: Ex vivo gene-edited cell medicine (AsCas12a)

Target HBG1/HBG2 promoter (gamma-globin)

Indications

Sickle cell disease / transfusion-dependent beta thalassemia (Stage not disclosed)

Status note Dec 2024: board approved discontinuation of clinical development; company ceased activities toward BLA filing and potential commercialization to optimize cost structure and accelerate in vivo gene editing. Approximately 180 positions (65%) eliminated in associated restructuring.

CD19 HD Allo CAR T (BMS program)

Phase 1 · Active Modality: Allogeneic CAR T

Target CD19

Partnerships BMS (via Juno Therapeutics): collaboration and license; Editas provides Cas9/AsCas12a platform; BMS funds and owns development. One of 14 programs under the collaboration; Immatics non-exclusive gamma-delta T cell collaboration programs not named.

Indications

Autoimmune disease (Phase 1)

Status note BMS' program using Editas platform technology; one of 14 programs under the BMS collaboration. Other named programs: Immatics non-exclusive gamma-delta T cell collaboration (programs not named).

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EDIT-301
Lead indication	Sickle Cell Disease
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04853576	Phase 2	Active, not recruiting	Sponsor	EDIT	—	Sickle Cell Disease; Hemoglobinopathies	—
NCT05444894	Phase 2	Active, not recruiting	Sponsor	EDIT	—	Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major	—
NCT06363760	Not disclosed	Enrolling by invitation	Sponsor	EDIT	—	Sickle Cell Disease; Transfusion-dependent Beta-Thalassemia; Hemoglobinopathies	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Editas Medicine, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	8,889,000	+8,889,000	1.35%	2026-08-14
RA Capital Management	8,889,000	+8,889,000	0.25%	2026-08-14
Vivo Capital	3,555,250	+3,555,250	1.05%	2026-08-14
Logos Global Management	2,222,000	+2,222,000	0.31%	2026-08-14
Casdin Capital	445,000	+445,000	0.07%	2026-08-14
DAFNA Capital	170,470	+170,470	0.11%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

EDIT — Editas Medicine Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

EDIT — Editas Medicine Inc.